This finding indicates that the microglia-limited MeCP2 deficit is sufficient to produce the symptoms of Rett’s syndrome and increases the importance of microglia in non-syndromic ASD forms, thus providing evidence that manipulating the immune response can have significant therapeutic potential. This evidence concerns the gene MECP2 and Rett syndrome.